Immutep Ltd · ASX:IMM
Immutep — Jefferies Virtual Healthcare Conference 2021
33 slides from Immutep's conference presentation, Jun 4, 2021
Slide 1: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics Jefferies Virtual Healthcare Conference June 1 – June 4, 2021 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: Overview
Overview For personal use only Immutep is an innovative biotechnology Collaboration deals executed company developing novel with industry leaders immunotherapies for cancer and autoimmune diseases Global leadership position in LAG-3 with four product candidates in immuno-oncology and Corporate Strat
Slide 4: LAG-3 Overview
For personal use only LAG-3 Overview - The most promising immune checkpoint -
Slide 5: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview Company Program Preclinical Phase I Phase II Phase III Total Trials Patients Eftilagimod Agonist For personal use only 10 4 14 940 Alpha(5) BMS Relatlimab 7 32 2 41 9,509 Validation Ieramilimab 1 4 “demonstrate a 5 960 benefit for patients”(6) Merck & Co. Inc. Fa
Slide 6: LAG-3 as a Therapeutic Target
LAG-3 as a Therapeutic Target For personal use only LAG-3, an immune checkpoint, is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells LAG-3 / MHC II interaction is a validated target for IO Positive regulation LAG-3 / MHC Class II Interaction of antigen presenting M
Slide 7: Targeting LAG-3 / MHC II: Multiple Therapeutics in Numerous Diseases
Targeting LAG-3 / MHC II: Multiple Therapeutics in Numerous Diseases For personal use only IMMUNOSTIMULATION IMMUNOSUPPRESSION Efti IMP761 APC activator Agonistic mAb APC Partnered with LAG-3 MHC II GSK’781 Partnered with Depleting mAb LAG525 T Cell Antagonistic mAb LAG-3 LAG-3 T Cell RELEVANT Immun
Slide 8: Immunotherapy Pipeline
Immunotherapy Pipeline* Commercial Program Preclinical Phase I Phase II Late Stage(5) Market Size(6) Rights For personal use only Metastatic Breast Cancer (Chemo – IO) US$29.9 billion AIPAC Non-Small-Cell Lung Carcinoma (IO – IO) (1) US$22.6 billion TACTI-002 Head and Neck Squamous Cell Carcinoma (I
Slide 9: Immutep Out-Licensed Immunotherapy Pipeline
Immutep Out-Licensed Immunotherapy Pipeline* For personal use only Commercial Program Preclinical Phase I Phase II Late Stage(1) Updates Rights/Partners Solid Tumors + Blood Cancer (IO-IO Combo) Triple Negative Breast Cancer (Chemo-IO Combo) Novartis currently has five clinical trials ongoing for On
Slide 10: Eftilagimod Alpha (efti or IMP321)
For personal use only Eftilagimod Alpha (efti or IMP321)
Slide 11: Efti: an Innovative LAG-3 IO Product Candidate
Efti: an Innovative LAG-3 IO Product Candidate For personal use only the only MHC II agonist (APC activator) product candidate currently in clinical development synergistic with other therapeutic agents and modalities e.g. IO agents or chemotherapy “PUSHING THE ACCELERATOR ON IMMUNE RESPONSES” “
Slide 12: Efti: Potential Pipeline in a Product
Efti: Potential Pipeline in a Product High intrinsic value For personal use only Unique APC activator (MHC II Agonist) Effective APC activation leads to immune activation (e.g. CD8 T cells) as shown by ex vivo and in vivo experiments, and in clinical studies Pipeline in a product - not limited to a
Slide 13: Efti + Chemo Combination: Exciting interim OS results
For personal use only Efti + Chemo Combination: Exciting interim OS results Presented at SABCS in December 2020
Slide 14: Efti: AIPAC (Phase IIb) design
Efti: AIPAC (Phase IIb) design AIPAC: Active Immunotherapy PAClitaxel in HER2-/ HR+ metastatic breast cancer (MBC) For personal use only Fact sheet Primary endpoint(*) (presented Mar. 2020) included: ✓ Conducted in 7 EU countries • Assessment of Progression-Free Survival (PFS) ✓ Local and blinded in
Slide 15: AIPAC Phase IIb Clinical Results
AIPAC Phase IIb Clinical Results Subgroups: low monocytes and < 65 years – PFS / OS / ORR For predefined sub-groups: For personal use only Clinically meaningful absolute and relative improvement for efficacy parameters, significance for OS ESMO scale of magnitude* = level 4 (makes reimbursement very
Slide 16: AIPAC Phase IIb Clinical Results: Immune Monitoring
AIPAC Phase IIb Clinical Results Immune Monitoring on Fresh Blood (up to 70 patients) For personal use only Cytotoxic CD8+ T Cell count over time Stat. significant (p=0.020) (Mean + SEM million cells/L of blood; Correlation: OS and cytotoxic CD8+ p-value Wilcoxon) T cell count CD8 T cell count at 6
Slide 17: AIPAC Phase IIb Clinical Results: Summary and Conclusions
AIPAC Phase IIb Clinical Results Summary and Conclusions For personal use only First time Proof of Principle an APC activator has shown meaningful Significant increase in cytotoxic T cell increase in Overall Survival (OS) in a numbers compared to placebo randomised setting Proof of Concept Path Forw
Slide 18: Efti + anti-PD-1 Combinations
For personal use only Efti + anti-PD-1 Combinations Update from ASCO 2021
Slide 19: Key Clinical Trials: TACTI-002 design & status
Key Clinical Trials TACTI-002 (Phase II) design & status TACTI-002: Two ACTive Immunotherapeutics in NSCLC and HNSCC For personal use only UNSELECTED FOR PD-L1 In collaboration with PART A: S 1ST LINE MET. NSCLC C R PART B: COMBINED E ORR, PFS, OS, PK, 2ND LINE MET. NSCLC, IMMUNOTHERAPY E PEMBROLIZU
Slide 20: TACTI-002: Part A baseline characteristics & efficacy
TACTI-002: Phase II of efti and pembro in 1st line met NSCLC (Part A) BASELINE CHARACTERISTICS & EFFICACY* For personal use only Baseline Disease Characteristics* Tumor Response* Local Read Blinded Read Baseline parameters N (%) Best overall response, iRECIST (investigator) (BICR) N (%) N (%) Age (y
Slide 21: TACTI-002: Part A efficacy
TACTI-002: Phase II of efti and pembro in 1st line met NSCLC (Part A) EFFICACY For personal use only ORR by PD-L1 subgroup* Overall PFS estimates by PD-L1 subgroup** PD-L1 ORR iRECIST* (%) PD-L1 Median PFS iRECIST* (months) ≥ 50% TPS 53.8 Unselected 8.2 Duration of Response < 50% TPS 31.6 ≥ 50% TPS
Slide 22: TACTI-002: Part C baseline characteristics & efficacy
TACTI-002: Phase II of efti and pembro in 2nd line HNSCC (Part C) BASELINE CHARACTERISTICS & EFFICACY* For personal use only Baseline disease characteristics Primary tumor location Tumor response* Baseline parameters Primary tumour Investigator N (%) N (%) Best overall response*, iRECIST (N=39) loca
Slide 23: TACTI-002: Part C efficacy
TACTI-002: Phase II of efti and pembro in 2nd line HNSCC (Part C) EFFICACY* For personal use only Waterfall plot** Kaplan-Meier Plot PFS* Duration of response (DOR) for 100 100 Best response: confirmed responders • Deep responses 90 Probability of Survival iUPD/iCPD CPS >=1 (n=24) 80 75 with 5 CRs i
Slide 24: INSIGHT-004: Phase I of efti and avelumab
INSIGHT-004*: Phase I of efti and avelumab For personal use only • INSIGHT-004 is a dose escalation study evaluating efti in combination with Bavenico ® (avelumab). Conducted as the 4th arm of the INSIGHT platform trial. • 12 pts (cohort 1: gastric, gallbladder, colon cancer, pleural mesothelioma; c
Slide 25: INSIGHT-005: Phase I for efti and bintrafusp alfa
INSIGHT-005: Phase I for efti and bintrafusp alfa To evaluate the feasibility and safety of combined treatment with bintrafusp alfa For personal use only (M7824) and eftilagimod alpha. Conducted as the 5th arm of the INSIGHT trial*. Institut für Klinisch-Onkologische Forschung In collaboration with
Slide 26: TACTI-003 Trial in 1st line HNSCC
TACTI-003 Trial in 1st line HNSCC Current Design + Status For personal use only TREATMENT A S Pembrolizumab + Efti C COHORT A RANDOMIZATION 1:1 R PD-L1 CPS ≥1 TREATMENT B ORR, PFS, OS, PK, E biomarker, safety and E Pembrolizumab alone tolerability N I N G COHORT B TREATMENT PD-L1 CPS <1 Pembrolizuma
Slide 27: IMP761 - Autoimmune Diseases
For personal use only IMP761 - Autoimmune Diseases -
Slide 28: Broad potential in targeting auto-reactive memory T cells with IMP761
Broad potential in targeting auto-reactive memory T cells with IMP761 For personal use only THE PRESENT: FIGHTING THE SYMPTOMS Treating general inflammation: corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs THE FUTURE: FIGHTING THE CAUSE Treating the disease process: silencing the fe
Slide 29: Corporate Snapshot & Outlook
For personal use only Corporate Snapshot & Outlook
Slide 30: Corporate Snapshot
Corporate Snapshot For personal use only IMM (ASX) Ticker symbols IMMP (NASDAQ) Securities on issue(1) (as at 1 June 2021) 696.1 million ordinary shares Cash & Cash equivalents (as at 31 March 2021) ~A$51.7 million (US$39.3 million) Market Cap(2) A$487.3 million (US$377.3 million) (as at 1 June 2021
Slide 31: 2020 & 2021 News Flow
2020 & 2021 News Flow* For personal use only 2020 2021 Final data from AIPAC: 2nd OS follow up AIPAC – PFS, ORR and OS delivered Data from TACTI-002 & final data from US IND for MBC INSIGHT-004 at ASCO TACTI-002 – recruitment & data delivered e.g. Recruitment & first data from TACTI-002
Slide 32: Summary
Summary For personal use only Global leadership position in Multiple active clinical trials LAG-3 with four LAG-3 (including partnered related product candidates in candidates), with further immuno-oncology and significant data read-outs in autoimmune disease 2021 Compelling clinical data from Estab
Slide 33: Thank You
For personal use only Thank You
Immutep — Jefferies Virtual Healthcare Conference 2021 on 6ix